Oramed Pharmaceuticals (ORMP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	42.10 mm	42.10 mm	42.10 mm	42.10 mm	42.10 mm	42.10 mm
Cash burn (monthly)	14.22 mm	(no burn)	6.17 mm	(no burn)	2.37 mm	659.92 k
Cash used (since last report)	75.54 mm	n/a	32.78 mm	n/a	12.58 mm	3.51 mm
Cash remaining	-33.44 mm	n/a	9.32 mm	n/a	29.53 mm	38.60 mm
Runway (months of cash)	-2.4	n/a	1.5	n/a	12.5	58.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

ORMP institutional ownership history Ownership history

25.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	57	60	-5.0%
Opened positions	9	10	-10.0%
Closed positions	12	3	+300.0%
Increased positions	14	13	+7.7%
Reduced positions	14	14	–

13F shares	Current	Prev Q	Change
Total value	16.90 bn	15.15 bn	+11.5%
Total shares	10.35 mm	7.28 mm	+42.2%
Total puts	2.10 k	0.00	NEW
Total calls	4.00 k	0.00	NEW
Total put/call ratio	0.5	–	–

Largest owners	Shares	Value	Change
BML Capital Management	2.19 mm	$5.33 bn	+62.1%
BML Investment Partners	2.05 mm	$5.08 mm	NEW
Murchinson	1.71 mm	$4.17 bn	+0.5%
Slager David Mark	1.34 mm	$5.70 mm	0.0%
Boothbay Fund Management	828.33 k	$2.02 bn	+0.4%
RAT Rathbone Brothers	289.80 k	$707.12 mm	0.0%
Two Sigma Advisers	255.60 k	$623.66 mm	-1.4%
Renaissance Technologies	245.30 k	$598.53 mm	+6.3%
BAC Bank of America	172.19 k	$420.15 mm	-0.6%
Two Sigma Investments	141.68 k	$345.71 mm	-5.8%

Largest transactions	Shares	Bought/sold	Change
BML Investment Partners	2.05 mm	+2.05 mm	NEW
BML Capital Management	2.19 mm	+837.15 k	+62.1%
Connor, Clark & Lunn Investment Management	111.52 k	+111.52 k	NEW
BlackRock	92.01 k	+92.01 k	NEW
BLK BlackRock	0.00	-89.71 k	EXIT
D. E. Shaw & Co.	0.00	-38.57 k	EXIT
Millennium Management	46.67 k	+27.21 k	+139.8%
Marshall Wace	22.53 k	+22.53 k	NEW
Citadel Advisors	21.40 k	+21.40 k	NEW
UBS UBS	28.18 k	+18.89 k	+203.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ORMP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
11 Feb 25	Kidron Miriam	Common Stock	Grant	Acquire A	No	No	66,667	1,193,333
11 Feb 25	Kidron Miriam	Common Stock	Grant	Acquire A	No	No	52,000	1,126,666
11 Feb 25	Kidron Miriam	Common Stock	Grant	Acquire A	No	No	74,000	1,074,666
11 Feb 25	Joshua Hexter	Common Stock	Grant	Acquire A	No	No	33,334	833,167
11 Feb 25	Joshua Hexter	Common Stock	Grant	Acquire A	No	No	48,500	799,833
11 Feb 25	Joshua Hexter	Common Stock	Grant	Acquire A	No	No	45,000	751,333
11 Feb 25	Kidron Nadav	Common Stock	Grant	Acquire A	No	No	100,000	2,686,598
11 Feb 25	Kidron Nadav	Common Stock	Grant	Acquire A	No	No	186,000	2,586,598
11 Feb 25	Kidron Nadav	Common Stock	Grant	Acquire A	No	No	141,000	2,400,598
11 Feb 25	Avraham Gabay	Common Stock	Grant	Acquire A	No	No	42,000	434,040

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Oramed Pharmaceuticals Issues Letter To Shareholders From President And CEO Nadav Kidron

4 Mar 25

Dear Shareholders,I am happy to take this opportunity to provide our shareholders with an overview of our key accomplishments and outline our future direction. Oramed-HTIT Joint Venture: OraTech - A Transformational

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

26 Feb 25

Scilex Announces Voluntary $13.2M Early Payment On Oramed Note, Full Retirement Set For March 2025

16 Dec 24

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatments for obesity, neurodegenerative,

Press releases

From Benzinga Pro

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

11 Feb 25

New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in